Why should i take drugs for your infection?: Outcomes of formative research on the use of HIV pre-exposure prophylaxis in Nigeria

BMC Public Health

Volumn 15, Issue 1, 2015, Pages

  Idoko, John ^a   Folayan, Morenike Oluwatoyin ^b,c   Dadem, Nancin Yusufu ^d   Kolawole, Grace Oluwatosin ^d   Anenih, James ^a   Alhassan, Emmanuel ^a  

^a NATIONAL AGENCY FOR THE CONTROL OF AIDS   (Nigeria)

^b OBAFEMI AWOLOWO UNIVERSITY   (Nigeria)

^c New HIV Vaccine and Microbicide Advocacy Society   (Nigeria)

^d UNIVERSITY OF JOS   (Nigeria)

Author keywords

Couples; Nigeria; PrEP; Resistance; Serodiscordant; Stigma

Indexed keywords

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; FEMALE; HIV INFECTIONS; HUMAN; INTERVIEW; MALE; METHODOLOGY; MOTIVATION; NIGERIA; PERCEPTION; PRE-EXPOSURE PROPHYLAXIS; PROCEDURES; PSYCHOLOGY; PUBLIC OPINION; SEXUALITY; YOUNG ADULT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; FEMALE; HIV INFECTIONS; HUMANS; INTERVIEWS AS TOPIC; MALE; MOTIVATION; NIGERIA; PERCEPTION; PRE-EXPOSURE PROPHYLAXIS; PUBLIC OPINION; RESEARCH DESIGN; SEXUAL PARTNERS; YOUNG ADULT;

EID: 84928041190     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/s12889-015-1690-9     Document Type: Article

References (34)

1. WHO report in partnership with UNICEF and UNAIDS: Global updatee on HIV treatment 2013: results, impact and opportunities. http://apps.who.int/iris/bitstream/10665/85326/1/9789241505734-eng.pdf. Accessed 10 April, 2015.
2. UNAIDS. Global report. 2012. http://www.avert.org/hiv-aids-nigeria.htm#sthash.UZ3ZAvpx.dpuf. Accessed 28th March, 2014.
3. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. N Engl J Med. 2010;363:2587-99.
4. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women. N Engl J Med. 2012;367:399-410.
5. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral Pre-exposure Prophylaxis for Heterosexual HIV Transmission in Botswana. N Engl J Med. 2012;367:423-34.
6. Choopanya K, Martin M, Suntharasamai Sangkum U, Mock PA, Leethochawalit M, for the Bangkok Tenofovir Study Group. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo controlled phase 3 trial. Lancet. 2013;381:2083-90.
7. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 Infection with Early Antiretroviral Therapy. N Engl J Med. 2011;365:493-505.
8. Federal Ministry of Health. Antenatal Clinic HIV Sentinel Survey. Abuja, Nigeria. 2010.
9. Federal Ministry of Health. National HIV and AIDS Reproductive Health Survey. Abuja, Nigeria. 2012.
10. Federal Ministry of Health. HIV Integrated Biological and Behavioural Sentinel Survey. Abuja, Nigeria. 2010.
11. Eluwa GI, Strathdee SA, Adebayo SB, Ahonsi B, Adebajo SB. A profile on HIV prevalence and risk behaviors among injecting drug users in Nigeria: Should we be alarmed? Drug Alcohol Depend. 2012;127:65-71.
12. Sagay AS, Onakewhor J, Galadanci H, Emuveyan EE. HIV status of partners of HIV positive pregnant women in different regions of Nigeria: matters arising. Afr J Med Med Sci. 2006;35:125-9.
13. Ikechebelu J, Mbamara SU, Joe-Ikechebebelu NN, Ezenwabachili AO. Sexual practices of people living with HIV in South Eastern Nigeria. Niger J Clin Pract. 2009;12:416-20.
14. Khamofu H. Discordancy trends in Nigeria's PMTCT programme. Presentation at the consultative meeting on the roadmap for moving forward the agenda for PrEP access in Nigeria. May 21-24, Abuja, Nigeria. 2012
15. Latkin CA, Knowlton AR. Micro-social structural approaches to HIV prevention: a social ecological perspective. AIDS Care. 2005;17:102-13.
16. Poundstone KE, Strathdee SA, Celentano DD. The social epidemiology of human immunodeficiency virus / acquired immunodeficiency syndrome. Epidemiol Rev. 2004;26:22-35.
17. Eshleman SH, Hudelson SE, Redd AD, Wang L, Debes R, Chen YQ, et al. Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial. J Infect Dis. 2011;204:1918-26.
18. Ngure K, Mugo N, Celum C, Baeten JM, Morris M, Olungah O, et al. A qualitative study of barriers to consistent condom use among HIV-1 serodiscordant couples in Kenya. AIDS Care. 2012;24:509-16.
19. Ndase P, Celum C, Thomas K, Donnell D, Fife KH, Bukusi E, et al. Outside sexual partnerships and risk of HIV acquisition for HIV uninfected partners in African HIV serodiscordant partnerships. J Acquir Immune Defic Syndr. 2012;59:65-71.
20. Anonymous. Trying to get pregnant and thankful for PrEP. Saturday, June 9, 982 2012. http://myprepexperience.blogspot.com/2012/06/trying-to-get-pregnant-and-thankfulfor.html. Accessed 10 April 2015.
21. Kitara DL, Aloyo J. HIV/AIDS Stigmatization, the reason for poor access to HIV counseling and testing (HCT) Among the Youths inGulu∈(Uganda). Afr J Infect Dis. 2012;6:12-20.
22. Makoae LN, Portillo CJ, Uys LR, Dlamini PS, Greeff M, Chirwa M, et al. The impact of taking or not taking ARVs on HIV stigma as reported by persons living with HIV infection in five African countries. AIDS Care. 2009;21:1357-62.
23. Ware NC, Wyatt MA, Tugenberg T. Social relationships,∈stigma and adherence to antiretroviral therapy for HIV/AIDS. AIDS Care. 2006;18:904-10.
24. Coates TJ, Szekeres G. Think tank: Policy and practice implications of HIV pre-exposure prophlaxis (PrEP) in the United States - Meeting proceedings. Los Angeles, CA: UCLA Program in Global Health; 2006.
25. Mack N, Mwale B, Lanham M, Hosseinipour M, Martinson F, Corneli A, et al. Anticipatory planning for PrEP rollout in Malawi based on country priorities. [abstract WEPE0261]. Mexico City, Mexico: XVII International AIDS Conference; 2008.
26. Van der Elst EM, Mbogua J, Operario D, Mutua G, Kuo C, Mugo P, et al. High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya. AIDS Behav. 2013;17:2162-72.
27. Underhill K, Operario D, Mimiaga MJ, Skeer MR, Mayer KH. Implementation science of pre-exposure prophylaxis:∈preparing for public use. Curr HIV/AIDS Rep. 2010;7:210-9.
28. Remien RH, Stirratt MJ, Dolezal C, Dognin JS, Wagner GJ, Carballo-Dieguez A, et al. Couple focused support to improve HIV medication adherence: randomized controlled trial. AIDS. 2005;19:807-14.
29. World Health Organisation. Gender Dimensions of HIV Status Disclosure to Sexual Partners: Rates, Barriers and Outcomes. 2004. http://www.who.int/gender/documents/en/VCTinformationsheet-%5B92%20KB%5D.pdf Accessed 29th March, 2014.
30. Hurt CB, Eron Jr JJ, Cohen MS. Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? Clin Infect Dis. 2011;53:1265-70.
31. Abbas UL, Hood G, Wetzel AW, Mellors JW. Factors influencing the emergence and spread of HIV drug resistance arising from rollout of antiretroviral pre-exposure prophylaxis (PrEP). PLoS One. 2011;6:e18165.
32. IRMA Rectal Micro. WE WON: CDC responds to Open Letter, commits to condom clarity! Posting on the 29th. 2014.
33. National Agency for the Control of AIDS. National Guidelines for Implementation of HIV Prevention Programs for Female Sex Workers in Nigeria. Abuja, Nigeria: NACA; 2013.
34. National Agency for the Control of AIDS. HIV Prevention and Treatment Program Intervention for People Who Inject Drugs in Nigeria. NACA: Abuja, Nigeria; 2014.